Cost-Analysis of Relapsing-Remitting Multiple Sclerosis in Italy after the Introduction of New Disease-Modifying Agents

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.24, Iss.7, 2004-01, pp. : 409-420

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Effectiveness Analyses of Natalizumab (Tysabri ® ) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

By Gani Ray

PharmacoEconomics, Vol. 26, Iss. 7, 2008-01 ,pp. : 617-627

Adis International

Access to resources Recommend Favorite

The Cost of Multiple Sclerosis and the Cost Effectiveness of Disease-Modifying Agents in its Treatment

By Phillips C.J.

CNS Drugs, Vol. 18, Iss. 9, 2004-01 ,pp. : 561-574

Adis International

Access to resources Recommend Favorite

Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents

By Amato Maria Pia

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 10, 2004-10 ,pp. : 2115-2126

Informa Healthcare

Access to resources Recommend Favorite

Cladribine tablets for the treatment of relapsing–remitting multiple sclerosis

By Comi Giancarlo Hartung Hans-Peter Kurukulasuriya Nuwan C Greenberg Steven J Scaramozza Matthew

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 1, 2013-01 ,pp. : 123-136

Informa Healthcare

Access to resources Recommend Favorite

Emerging oral drugs for relapsing–remitting multiple sclerosis

By Gasperini Claudio Ruggieri Serena

Expert Opinion on Emerging Drugs, Vol. 16, Iss. 4, 2011-12 ,pp. : 697-712

Informa Healthcare

Access to resources Recommend Favorite